BioSpace News Archive

Alloy Therapeutics announced the launch of its novel AntiClastic™ Antisense Oligonucleotide (AntiClastic ASO) platform, which employs optimally created spatial conformation nucleic acids that further enhance the drug-like properties of antisense.

Amplifica Holdings Group, Inc. (“Amplifica”), a privately held, clinical-stage biopharmaceutical company announced the initiation of the first-in-human study of its lead candidate AMP-303.

Ambrx Biopharma Inc., or Ambrx (or the “Company”) (NASDAQ: AMAM), today announced the closing of its previously announced market-priced registered direct offering of approximately $75 million (the “Offering”) of its American Depositary Shares of the Company (“ADS”) at a price of $13.93 per ADS.

Biora Therapeutics, Inc today announced that it has been awarded a group of US and European patents related to several additional therapeutic targets for its NaviCap™ targeted oral delivery platform under development.

Genprex, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) for the Company’s lead drug candidate, REQORSA® Immunogene Therapy, in combination with Genentech, Inc.'s Tecentriq® in patients with extensive-stage small cell lung cancer (ES-SCLC) who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment.

JanOne Inc. (Nasdaq: JAN), a biopharmaceutical company that is developing multiple drugs to treat chronic diseases like Peripheral Artery Disease (PAD) and Complex Regional Pain Syndrome (CRPS), has just filed an international patent application for methods of using low dose naltrexone to treat chronic pain.

Blue Earth Therapeutics Announces Results of Early Clinical and Preclinical Studies of Investigational 177 Lu-rhPSMA-10.1 in Treatment of Prostate Cancer.

Sinoveda is an innovative Canadian-based health brand that is bringing Eastern and Western Medicine together.

Reflect Scientific, Inc., a leading provider of innovative cold storage solutions, is pleased to announce the receipt of a significant order for their state-of-the-art B-90 plasma freezer.

Axsome Therapeutics, Inc. today announced the pricing of an underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $75.00 per share.